drugset
drugset / Trial / NCT02989389

A Study of LY3323795 in Healthy Participants

NCT02989389 ↗

Phase 1 Completed 42 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to investigate the safety of LY3323795 and the effects it has on the body. The study drug or placebo (sugar pill) will be given by mouth to healthy participants. The study has three parts. Each participant may only enroll in one part. The study will last 14 to 43 days, depending on the part. Screening must be completed prior to study start.

Timeline

Start
2016-12-12
Primary completion
2017-07-21
Completion
2017-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3323795 Unknown 0.3 mg Oral
Subject LY3323795 Unknown 1 mg Oral
Subject LY3323795 Unknown 3 mg Oral
Subject LY3323795 Unknown 6 mg Oral
Subject LY3323795 Unknown 10 mg Oral
Subject LY3323795 Unknown 20 mg Oral
Subject LY3323795 Unknown 30 mg Oral
Subject LY3323795 Unknown 80 mg Oral
Subject LY3323795 Unknown 100 mg Oral
Background Itraconazole Small molecule — Oral

Indications

No indication recorded.